These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31597900)

  • 1. [Mechanisms of hepatic stellate cell activation as a therapeutic target for the treatment of non-alcoholic steatohepatitis].
    Tsuchida T
    Nihon Yakurigaku Zasshi; 2019; 154(4):203-209. PubMed ID: 31597900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of hepatic stellate cell activation.
    Tsuchida T; Friedman SL
    Nat Rev Gastroenterol Hepatol; 2017 Jul; 14(7):397-411. PubMed ID: 28487545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease.
    Liang D; Chen H; Zhao L; Zhang W; Hu J; Liu Z; Zhong P; Wang W; Wang J; Liang G
    Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):133-142. PubMed ID: 29038049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
    Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
    Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
    Wiering L; Subramanian P; Hammerich L
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
    Thomsen KL; De Chiara F; Rombouts K; Vilstrup H; Andreola F; Mookerjee RP; Jalan R
    Med Hypotheses; 2018 Apr; 113():91-97. PubMed ID: 29523305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional regulation of Hepatic Stellate Cell activation in NASH.
    Marcher AB; Bendixen SM; Terkelsen MK; Hohmann SS; Hansen MH; Larsen BD; Mandrup S; Dimke H; Detlefsen S; Ravnskjaer K
    Sci Rep; 2019 Feb; 9(1):2324. PubMed ID: 30787418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-Mediated RNA Therapy Attenuates Nonalcoholic Steatohepatitis and Related Fibrosis by Targeting Activated Hepatic Stellate Cells.
    Zhang C; Teng Y; Li F; Ho W; Bai X; Xu X; Zhang XQ
    ACS Nano; 2023 Aug; 17(15):14852-14870. PubMed ID: 37490628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
    Subramanian P; Hampe J; Tacke F; Chavakis T
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.
    Kumar S; Duan Q; Wu R; Harris EN; Su Q
    Adv Drug Deliv Rev; 2021 Sep; 176():113869. PubMed ID: 34280515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.